Evidence map›Paper›PMID 35897737›Full record

ArticleInternational journal of molecular sciences2022

The Pt(

Zana Besser Silconi, Vesna Rosic, Sasa Benazic, Gordana Radosavljevic, Marina Mijajlovic, Jelena Pantic, Zoran R Ratkovic, Gordana Radic, Aleksandar Arsenijevic, Marija Milovanovic and 2 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Metal-Based Complexes in Cancer.International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Zana Besser SilconiDepartment of Cytology, Pula General Hospital, 52100 Pula, Croatia.
Vesna RosicDepartment of Histology and Embryology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.ORCID 0000-0002-4264-845X
Sasa BenazicDepartment of Transfusiology, Pula General Hospital, 52100 Pula, Croatia.
Gordana RadosavljevicCenter for Molecular Medicine & Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
Marina MijajlovicDepartment of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.ORCID 0000-0002-7177-4666
Jelena PanticCenter for Molecular Medicine & Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
Zoran R RatkovicDepartment of Chemistry, Faculty of Science, University of Kragujevac, 34000 Kragujevac, Serbia.
Gordana RadicDepartment of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
Aleksandar ArsenijevicCenter for Molecular Medicine & Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
Marija MilovanovicCenter for Molecular Medicine & Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
Nebojsa ArsenijevicCenter for Molecular Medicine & Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
Jelena MilovanovicDepartment of Histology and Embryology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
University of Kragujevac · RSJuraj Dobrila University of Pula · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

B cell malignancies are, despite the development of targeted therapy in a certain percentage of the patients still a chronic disease with relapses, requiring multiple lines of therapy. Regimens that include platinum-based drugs provide high response rates in different B cell lymphomas, high-risk chronic lymphocytic leukemia (CLL), and devastating complication of CLL, Richter's syndrome. The aim of this study was to explore the potential antitumor activity of previously synthetized platinum(IV) complex with alkyl derivatives of thyosalicilc acid, PtCl2(

Indexed as

LeukemiaLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Large B-Cell, DiffuseAnimalsCell CycleCyclin D3MiceCyclin D3antitumor activityBCL1Bcl-2Pt(S-pr-thiosal)2 complexSTAT3

Identifiers

PMID35897737
PMCPMC9332548
OpenAlexW4287009673

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.